pFARs, plasmids free of antibiotic resistance markers, display high-level transgene expression in muscle, skin and tumour cells

Journal of Gene Medicine

Volumn 12, Issue 4, 2010, Pages 323-332

  Marie, Corinne ^a   Vandermeulen, Gaëlle ^b   Quiviger, Mickaël ^a   Richard, Magali ^a   Préat, Véronique ^b   Scherman, Daniel ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Biosafety; DNA delivery; Electrotransfer; Gene therapy; Nonviral; Plasmid vector

Indexed keywords

BIOLOGICAL MARKER; KANAMYCIN; LUCIFERASE; MONOMER; PLASMID FREE OF ANTIBIOTIC RESISTANCE MARKER; PLASMID VECTOR; PROTEIN THYA; THYMIDINE; TRANSFER RNA; UNCLASSIFIED DRUG;

AMBER MUTANT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ARTICLE; AUXOTROPHY; BACTERIAL GROWTH; BACTERIAL STRAIN; CHROMOSOME; CONTROLLED STUDY; ELECTROPORATION; ENZYME ACTIVITY; ESCHERICHIA COLI; EUKARYOTE; FEMALE; GENE EXPRESSION; GENE TARGETING; GENE VECTOR; MALE; MOUSE; MUSCLE CELL; NONHUMAN; NONSENSE MUTATION; NONVIRAL GENE DELIVERY SYSTEM; NUCLEOTIDE SEQUENCE; PLASMID; PRIORITY JOURNAL; SKIN CELL; TRANSGENE; TUMOR CELL;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; EUKARYOTA;

EID: 77950896663     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1441     Document Type: Article

References (49)

1. Somia N, Verma IM. Gene therapy: trials and tribulations. Nat Rev Genet 2000; 1: 91-99.
2. Li Z, Düllmann J, Schiedlmeier B, et al. Murine leukemia induced by retroviral gene making. Science 2002; 296: 497. (Pubitemid 34408663)
3. Flotte TR. Gene therapy progress and prospects: recombinant adeno-associated virus (rAAV) vectors. Gene Ther 2004; 11: 805-811.
4. Zaiss AK, Muruve DA. Immunity to adeno-associated virus vectors in animals and humans: a continued challenge. Gene Ther 2008; 15: 808-816.
5. Wolff JA, Ludtke JJ, Acsadi G, Williams P, Jani A. Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle. Hum Mol Genet 1992; 1: 363-369.
6. Zhang G, Song YK, Liu D. Long-term expression of human alpha1-antitrypsin gene in mouse liver achieved by intravenous administration of plasmid DNA using a hydrodynamics-based procedure. Gene Ther 2000; 7: 1344-1349. (Pubitemid 30623783)
7. Liu F, Song YK, Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 1999; 6: 1258-1266. (Pubitemid 29359019)
8. Bloquel C, Fabre E, Bureau MF, Scherman D. Plasmid DNA electrotransfer for intracellular and secreted proteins expression: new methodological developments and applications. J Gene Med 2004; 6: S11-S13. (Pubitemid 40228013)
9. Lopez-Fuertes L, Pérez-Jiménez E, Vila-Coro AJ, et al. DNA vaccination with linear minimalistic (MIDGE) vectors confers protection against Leishmania major infection in mice. Vaccine 2002; 21: 247-257. (Pubitemid 35346820)
10. Kreiss P, Cameron B, Darquet AM, Scherman D, Crouzet J. Production of a new DNA vehicle for gene transfer using site-specific recombination. Appl Microbiol Biotechnol 1998; 49: 560-567. (Pubitemid 28267248)
11. Chen Z-Y, He C-Y, Ehrhardt A, Kay MA. Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. Mol Ther 2003; 8: 495-500. (Pubitemid 37161471)
12. Chen Z-Y, He C-Y, Kay MA. Improved production and purification of minicircle DNA vector free of plasmid bacterial sequences and capable of persistent transgene expression in vivo. Hum Gene Ther 2005; 16: 126-131.
13. Riu E, Chen Z-Y, Xu H, He C-Y, Kay MA. Histone modifications are associated with the persistence or silencing of vector-mediated transgene expression in vivo. Mol Ther 2007; 15: 1348-1355. (Pubitemid 46965331)
14. Cranenburgh RM, Hanak JAJ, Williams SG, Sherratt DJ. Escherichia coli strains that allow antibiotic-free plasmid selection and maintenance by repressor titration. Nucleic Acids Res 2001; 29: E26.
15. Cranenburgh RM, Lewis KS, Hanak JAJ. Effect of plasmid copy number and lac operator sequence on antibiotic-free plasmid selection by operator-repressor titration in Escherichia coli. J Mol Microbiol Biotechnol 2004; 7: 197-203.
16. Soubrier F, Cameron B, Manse B, et al. pCOR: a new design of plasmid vectors for nonviral gene therapy. Gene Ther 1999; 6: 1482-1488. (Pubitemid 29396737)
17. Soubrier F, Laborderie B, Cameron B. Improvement of pCOR plasmid copy number for pharmaceutical applications. Appl Microbiol Biotechnol 2005; 66: 683-688. (Pubitemid 40385632)
18. Pfaffenzeller I, Mairhofer J, Striedner G, Bayer K, Grabherr R. Using ColE1-derived RNA I for suppression of a bacterially encoded gene: implication for a novel plasmid addiction system. Biotechnol J 2006; 1: 675-681.
19. Mairhofer J, Pfaffenzeller I, Merz D, Grabherr R. A novel antibiotic free plasmid selection system: advances in safe and efficient DNA therapy. Biotechnol J 2008; 3: 83-89. (Pubitemid 351200934)
20. Luke J, Carnes AE, Hodgson CP, Williams JA. Improved antibiotic-free DNA vaccine vectors utilizing a novel RNA based plasmid selection system. Vaccine 2009; 27: 6454-6459.
21. Vandermeulen G, Staes E, Vanderhaeghen ML, et al. Optimisation of intradermal DNA electrotransfer for immunisation. J Control Release 2007; 124: 81-87. (Pubitemid 350088207)
22. Rols MP. Mechanism by which electroporation mediates DNA migration and entry into cells and targeted tissues. Methods Mol Biol 2008; 423: 19-33.
23. Mir LM, Bureau MF, Gehl J, et al. High-efficiency gene transfer into skeletal muscle mediated by electric pulses. Proc Natl Acad Sci USA 1999; 96: 4262-4267. (Pubitemid 29190324)
24. Sambrook J, Fritsch EF, Maniatis T (eds). Molecular Cloning: A Laboratory Manual, 2nd edn. Cold Spring Harbour Laboratory Press: Cold Spring Harbor, NY, 1989.
25. Müller JH, Hinton J. A protein-freemedium for primary isolation of the Gonococcus and Meningococcus. Proc Soc Exp Biol Med 1941; 48: 330-333.
26. Hanahan D. Studies on transformation of Escherichia coli with plasmids. J Mol Biol 1983; 166: 557-580. (Pubitemid 13027898)
27. Blattner FR, Plunkett III G, Bloch CA, et al. The complete genome sequence of Escherichia coli K-12. Science 1997; 277: 1453-1462. (Pubitemid 27449228)
28. Posfai G, Kolisnychenko V, Bereczki Z, Blattner FR. Markerless gene replacement in Escherichia coli stimulated by a double-strand break in the chromosome. Nucleic Acids Res 1999; 27: 4409-4415. (Pubitemid 29533182)
29. Bloquel C, Bejjani RA, Bigey P, et al. Plasmid electrotransfer of eye ciliary muscle: principles and therapeutic efficacy using hTNF-α soluble receptor in uveitis. FASEB J 2006; 20: 389-391. (Pubitemid 46671181)
30. Normanly J, Kleina LG, Masson J-M, et al. Construction of Escherichia coli amber suppressor tRNA genes. III. Determination of tRNA specificity. J Mol Biol 1990; 213: 719-726. (Pubitemid 20213211)
31. Bloquel C, Trollet C, Pradines E, et al. Optical imaging of luminescence for in vivo quantification of gene electrotransfer in mouse muscle and knee. BMC Biotechnology 2006; 6: 16.
32. Pavselj N, Préat V. DNA electrotransfer into the skin using a combination of one high- and low-voltage pulse. J Control Release 2005; 106: 407-415. (Pubitemid 41187449)
33. André FM, Gehl J, Sersa G, et al. Efficiency of high- and low-voltage pulse combinations for gene electrotransfer in muscle, liver, tumor, and skin. Hum Gene Ther 2008; 19: 1261-1271.
34. Neuhard J, Kelln RA. Biosynthesis and conversions of pyrimidines. In Escherichia coli and Salmonella typhimurium: Cellular and Molecular Biology, Neidhardt FC (ed.). American Society for Microbiology: Washington, DC, 1996; 580-599.
35. Bopp CA, Wells JG, Barrett TJ. Trimethoprim activity in media selective for Campylobacter jejuni. J Clin Microbiol 1982; 16: 808-812.
36. Kleina LG, Masson J-M, Normanly J, Abelson J, Miller JH. Construction of Escherichia coli amber suppressor tRNA genes. II. Synthesis of additional tRNA genes and improvement of suppressor efficiency. J Mol Biol 1990; 213: 705-717. (Pubitemid 20213210)
37. CUA. Proc Natl Acad Sci USA 1986; 83: 6548-6552.
38. World Health Organization. Guidelines for Assuring the Quality and Nonclinical Safety Evaluation of DNA Vaccines. Adopted by the 56th meeting of the WHO Expert Committee on Biological Standardisation. WHO: Geneva, 2005.
39. Food and Drug Administration. Guidance for Industry: Considerations for Plasmid DNA Vaccines for Infectious Disease. November 2007; http://www.fda.gov/ cber/guidelines.htm.
40. Schoenfeld T, Mendez J, Storts DR, et al. Effects of bacterial strains carrying the endA1 genotype on DNA quality isolated with Wizard (TM) plasmid purification systems. Promega Notes Magazine 1995; 53: 12.
41. Marshall B, Levy SB. Prevalence of amber suppressor-containing coliforms in the natural environment. Nature 1980; 286: 524-525. (Pubitemid 10017693)
42. Poole ES, Brown CM, Tate WP. The identity of the base following the stop codon determines the efficiency of in vivo translational termination in Escherichia coli. EMBO Journal 1995; 14: 151-158.
43. MichaelsML, KimCW, Mattews DA, Miller JH. Escherichia coli thymidylate synthase: amino acid substitutions by suppression of amber nonsense mutations. Proc Natl Acad Sci USA 1990; 87: 3957-3961. (Pubitemid 20182579)
44. Krieg AM, Yi A-K, Matson S, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995; 374: 546-549.
45. Chaung H-C. CpG oligodeoxynucleotides as DNA adjuvants in vertebrates and their applications in immunotherapy. Int Immunopharmacol 2006; 6: 1586-1596.
46. Bauer S, Kirschning CJ, Häcker H, et al. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci USA 2001; 98: 9237-9242. (Pubitemid 32743900)
47. Lu QL, Bou-Gharios G, Partridge TA. Non-viral gene delivery in skeletal muscle: a protein factory. Gene Ther 2003; 10: 131-142. (Pubitemid 36582585)
48. Bodles-Brakhop AM, Heller R, Draghia-Akli R. Electroporation for the delivery of DNA-based vaccines and immunotherapeutics: current clinical developments. Mol Ther 2009; 17: 585-592.
49. Lucas ML, Heller L, Coppola D, Heller R. IL-12 plasmid delivery by in vivo electroporation for the successful treatment of established subcutaneous B110 melanoma. Mol Ther 2002; 5: 668-675. (Pubitemid 34624563)